Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | PROMENADE: highlighting TNBC in younger patients with aggressive features

Francois Cherifi • 15 Sep 2024
ESMO 2024
Breast Cancer

Francois Cherifi, MD, CLCC Francois Baclesse, Caen, France, discusses key insights from the PROMENADE study, which included 114 patients with ER-low triple-negative breast cancer (TNBC), and with a median age of 49, indicating a relatively younger cohort. Most patients presented with aggressive grade 3 features. The study also noted a high rate of uninterrupted chemotherapy and a predominance of tumorectomy as the surgical approach. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois Cherifi

Insights from the PROMENADE study on ER-low triple-negative breast cancer
0:30
Insights from the PROMENADE study on ER-low triple-negative breast cancer
Francois Cherifi • 15 Sep 2024
Rethinking thresholds in ER-Low TNBC for future studies
0:50
Rethinking thresholds in ER-Low TNBC for future studies
Francois Cherifi • 15 Oct 2024
Reevaluating treatment approaches for ER-Low TNBC
0:47
Reevaluating treatment approaches for ER-Low TNBC
Francois Cherifi • 15 Sep 2024
Real-world insights on pembrolizumab for ER-low triple-negative breast cancer
2:46
Real-world insights on pembrolizumab for ER-low triple-negative breast cancer
Francois Cherifi • 15 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals